Connecting via Winsock to STN

Welcome to STN International! Enter x:x

FILE 'HOME' ENTERED AT 10:19:32 ON 22 JAN 2009

=> file casreact

=>

Uploading C:\Program Files\Stnexp\Queries\10560823process.str

12 13 14 15 16 27 28 29 45 46 47 48 ring nodes : $1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 17 \quad 18 \quad 19 \quad 20 \quad 21 \quad 22 \quad 23 \quad 24 \quad 25 \quad 26 \quad 31 \quad 32$ 33 34 35 36 37 38 39 40 41 42 43 44 chain bonds : $1-11 \quad 6-29 \quad 7-12 \quad 8-13 \quad 10-17 \quad 13-14 \quad 13-15 \quad 15-16 \quad 22-24 \quad 24-27 \quad 27-28 \quad 31-37$ 35-48 36-47 40-42 42-45 45-46 ring bonds : $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 4-7 \quad 5-6 \quad 5-10 \quad 7-8 \quad 8-9 \quad 9-10 \quad 11-20 \quad 11-23 \quad 17-18 \quad 17-19$ 18-19 20-21 21-22 22-23 24-25 24-26 25-26 31-32 31-36 35-36 37-38 37-41 38-39 39-40 40-41 42-43 42-44 43-44 32-33 33-34 34-35 exact/norm bonds : $1-11 \quad 4-7 \quad 5-10 \quad 6-29 \quad 7-8 \quad 7-12 \quad 8-9 \quad 9-10 \quad 10-17 \quad 11-20 \quad 11-23 \quad 24-27 \quad 31-37$ 36-47 37-38 37-41 38-39 39-40 40-41 42-43 42-44 42-45 43-44exact bonds : $8-13 \quad 15-16 \quad 17-18 \quad 17-19 \quad 18-19 \quad 20-21 \quad 21-22 \quad 22-23 \quad 22-24 \quad 24-25 \quad 24-26 \quad 25-26$ 27-28 35-48 40-42 45-46

Page 1

chain nodes :

```
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 13-14 \quad 13-15 \quad 31-32 \quad 31-36 \quad 32-33 \quad 33-34 \quad 34-35
35 - 36
isolated ring systems :
containing 1 : 11 : 17 : 24 :
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS
28:CLASS 29:CLASS 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS
fragments assigned product role:
containing 1
fragments assigned reactant/reagent role:
containing 31
L1 STRUCTURE UPLOADED
=> d 11
L1 HAS NO ANSWERS
        STR
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.
=> s 11 sam
SAMPLE SEARCH INITIATED 10:20:11 FILE 'CASREACT'
SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS
100.0% DONE 0 VERIFIED 0 HIT RXNS
                                                                 0 DOCS
SEARCH TIME: 00.00.01
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH COMPLETE PROJECTED VERIFICATIONS: 0 TO 0 0 TO 0
            0 SEA SSS SAM L1 ( 0 REACTIONS)
L2
=> s 11 full
FULL SEARCH INITIATED 10:20:15 FILE 'CASREACT'
SCREENING COMPLETE - 13 REACTIONS TO VERIFY FROM 2 DOCUMENTS
100.0% DONE 13 VERIFIED 0 HIT RXNS
                                                                 0 DOCS
SEARCH TIME: 00.00.01
    0 SEA SSS FUL L1 ( 0 REACTIONS)
=> file react
```

10/560,823process

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 123.13 123.35

FILE 'CASREACT' ENTERED AT 10:20:21 ON 22 JAN 2009 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CHEMINFORMRX' ENTERED AT 10:20:21 ON 22 JAN 2009 COPYRIGHT (C) FIZ-CHEMIE BERLIN

FILE 'DJSMONLINE' ENTERED AT 10:20:21 ON 22 JAN 2009 COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'PS' ENTERED AT 10:20:21 ON 22 JAN 2009 COPYRIGHT (C) 2009 Thieme on STN

=> s 11 full

FULL SEARCH INITIATED 10:20:24 FILE 'CASREACT'

SCREENING COMPLETE - 13 REACTIONS TO VERIFY FROM 2 DOCUMENTS

100.0% DONE 13 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL SEARCH INITIATED 10:20:25 FILE 'CHEMINFORMRX'

SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL SEARCH INITIATED 10:20:28 FILE 'DJSMONLINE'

SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL SEARCH INITIATED 10:20:29 FILE 'PS'

SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

L4 0 L1

=>

Uploading C:\Program Files\Stnexp\Queries\823process2.str

```
chain nodes :
12 13 14 15 16 20 29 30
ring nodes :
1 \quad \overset{.}{2} \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 17 \quad 18 \quad 19 \quad 22 \quad 23 \quad 24 \quad 25 \quad 26 \quad 27 \quad 28
chain bonds :
1-11 \quad 6-20 \quad 7-12 \quad 8-13 \quad 10-17 \quad 13-14 \quad 13-15 \quad 15-16 \quad 22-28 \quad 26-30 \quad 27-29
ring bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 4-7 \quad 5-6 \quad 5-10 \quad 7-8 \quad 8-9 \quad 9-10 \quad 17-18 \quad 17-19 \quad 18-19 \quad 22-23
22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
1-11 4-7 5-10 6-20 7-8 7-12 8-9 9-10 10-17 22-28 27-29
exact bonds :
8-13 15-16 17-18 17-19 18-19 26-30
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 13-14 \quad 13-15 \quad 22-23 \quad 22-27 \quad 23-24 \quad 24-25 \quad 25-26
26-27
isolated ring systems :
containing 1 : 11 : 17 : 22 :
```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS 30:CLASS

Match level:

10/560,823process

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STF

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15 full

FULL SEARCH INITIATED 10:22:27 FILE 'CASREACT'

SCREENING COMPLETE - 2009 REACTIONS TO VERIFY FROM 94 DOCUMENTS

100.0% DONE 2009 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL SEARCH INITIATED 10:22:28 FILE 'CHEMINFORMRX'

SCREENING COMPLETE - 32 REACTIONS TO VERIFY FROM 6 DOCUMENTS

100.0% DONE 32 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.03

FULL SEARCH INITIATED 10:22:32 FILE 'DJSMONLINE'

SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL SEARCH INITIATED 10:22:33 FILE 'PS'

SCREENING COMPLETE - 4 REACTIONS TO VERIFY FROM 2 DOCUMENTS


100.0% DONE 4 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

L6 0 L5

=> file reg

Uploading C:\Program Files\Stnexp\Queries\823cmpd2.str



chain nodes : 15 16 17 18

10/560,823process

ring nodes:
1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds:
1-7 5-18 6-17 10-12 12-15 15-16

ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-14 13-14

exact/norm bonds:
1-7 6-17 7-8 7-11 8-9 9-10 10-11 12-13 12-14 12-15 13-14

exact bonds:
5-18 10-12 15-16


normalized bonds:
1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L7 STRUCTURE UPLOADED

=> d 17 L7 HAS NO ANSWERS L7 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10560823compound.str

```
chain nodes :
12 13 14 15 16 27 28 29
ring nodes :
1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 17 \quad 18 \quad 19 \quad 20 \quad 21 \quad 22 \quad 23 \quad 24 \quad 25 \quad 26
chain bonds :
1-11 \quad 6-29 \quad 7-12 \quad 8-13 \quad 10-17 \quad 13-14 \quad 13-15 \quad 15-16 \quad 22-24 \quad 24-27 \quad 27-28
ring bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 4-7 \quad 5-6 \quad 5-10 \quad 7-8 \quad 8-9 \quad 9-10 \quad 11-20 \quad 11-23 \quad 17-18 \quad 17-19
 18-19 20-21 21-22 22-23 24-25 24-26 25-26
exact/norm bonds :
1-11 \quad 4-7 \quad 5-10 \quad 6-29 \quad 7-8 \quad 7-12 \quad 8-9 \quad 9-10 \quad 10-17 \quad 11-20 \quad 11-23 \quad 24-27
exact bonds :
8-13 \quad 15-16 \quad 17-18 \quad 17-19 \quad 18-19 \quad 20-21 \quad 21-22 \quad 22-23 \quad 22-24 \quad 24-25 \quad 24-26 \quad 25-26
27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-15
isolated ring systems :
containing 1 : 11 : 17 : 24 :
```

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS 29:CLASS

```
L8 STRUCTURE UPLOADED
```

=> s 17 full

L9 5 SEA SSS FUL L7

=> s 18 full

L10 19 SEA SSS FUL L8

=> file ca

=> d his (FILE 'HOME' ENTERED AT 10:19:32 ON 22 JAN 2009) FILE 'CASREACT' ENTERED AT 10:19:43 ON 22 JAN 2009 L1STRUCTURE UPLOADED L2 0 S L1 SAM L3 0 S L1 FULL FILE 'CASREACT, CHEMINFORMRX, DJSMONLINE, PS' ENTERED AT 10:20:21 ON 22 JAN 2009 L40 S L1 L5 STRUCTURE UPLOADED L6 0 S L5 FILE 'REGISTRY' ENTERED AT 10:24:33 ON 22 JAN 2009 L7 STRUCTURE UPLOADED L8 STRUCTURE UPLOADED L9 5 S L7 FULL 19 S L8 FULL L10 FILE 'CA' ENTERED AT 10:25:29 ON 22 JAN 2009 => s 19 full L11 1 L9 => s 110 full L12 40 L10 => s 111 and 112 L13 1 L11 AND L12 => d ibib abs L13 ANSWER 1 OF 1 CA COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 142:93693 CA TITLE: Process for preparation of quinolinone derivatives INVENTOR(S): Muto, Makoto; Kitagawa, Yutaka PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan SOURCE: PCT Int. Appl., 23 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE _____ ____ _____ ______ WO 2004113321 A1 20041229 WO 2004-JP8607 20040618 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

```
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1634879
                                            EP 2004-746109
                          Α1
                                20060315
                                                                    20040618
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     US 20060122396
                                20060608
                                            US 2005-560823
                                                                    20051215
                          Α1
PRIORITY APPLN. INFO.:
                                            JP 2003-175212
                                                                A 20030619
                                            WO 2004-JP8607
                                                                W 20040618
OTHER SOURCE(S):
                        MARPAT 142:93693
GI
```

This invention pertains to a method for position-selectively introducing an amino group into a difluorobenzoic acid compound; a novel process for producing quinolinone derivs. I [wherein A = a protecting group; R1 = alkyl]. For example, the compound I [where A = tert-BuO2C; R1 = Me] was prepared in a multi-step synthesis starting from 2,4-difluoro-3-methoxybenzoic acid and (3R)-3-[1-(tert-butoxycarbonylamino)cyclopropyl]pyrrolidine. This invention provides a convenient method for regioselective amination of difluorobenzoic acid compound

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\phen.str

10/560,823process

chain nodes :
7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5 6
chain bonds :
1-9 4-10 5-8 6-7 7-13 10-11 10-12 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
6-7 7-13 10-11 10-12 12-14
exact bonds :
1-9 4-10 5-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L14 STRUCTURE UPLOADED

=> d 114 L14 HAS NO ANSWERS L14 STR

Structure attributes must be viewed using STN Express query preparation.

```
=> s 114 full
L15 148 SEA SSS FUL L14
=> file ca
=> s 115
          88 L15
L16
=> d his
     (FILE 'HOME' ENTERED AT 10:19:32 ON 22 JAN 2009)
     FILE 'CASREACT' ENTERED AT 10:19:43 ON 22 JAN 2009
L1
               STRUCTURE UPLOADED
              0 S L1 SAM
L2
L3
             0 S L1 FULL
    FILE 'CASREACT, CHEMINFORMRX, DJSMONLINE, PS' ENTERED AT 10:20:21 ON 22
     JAN 2009
L4
             0 S L1
L5
               STRUCTURE UPLOADED
             0 S L5
L6
    FILE 'REGISTRY' ENTERED AT 10:24:33 ON 22 JAN 2009
L7
               STRUCTURE UPLOADED
               STRUCTURE UPLOADED
L8
             5 S L7 FULL
L9
            19 S L8 FULL
L10
    FILE 'CA' ENTERED AT 10:25:29 ON 22 JAN 2009
L11
            1 S L9 FULL
L12
            40 S L10 FULL
L13
            1 S L11 AND L12
```

T.14

```
L15
          148 S L14 FULL
    FILE 'CA' ENTERED AT 10:27:47 ON 22 JAN 2009
L16
      88 S L15
=> s 116 and 112
           1 L16 AND L12
=> s 110/prep
            40 L10
       4701185 PREP/RL
           10 L10/PREP
L18
                 (L10 (L) PREP/RL)
=> d 1-10 ibib abs fhitstr
L18 ANSWER 1 OF 10 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:
                        149:493695 CA
TITLE:
                        Method for producing quinolonecarboxylic acid
                        derivatives
                      Sato, Koji; Sakuratani, Kenji
Daiichi Sankyo Company, Limited, Japan
INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
                        PCT Int. Appl., 32pp.
                        CODEN: PIXXD2
                        Patent
DOCUMENT TYPE:
LANGUAGE:
                        Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
    PATENT NO. KIND DATE APPLICATION NO.
                                                                DATE
     WO 2008126384
                        A1 20081023 WO 2008-JP817 20080331
        W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
            CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
            ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
            PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
            AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: JP 2007-90650
OTHER SOURCE(S): CASREACT 149:493695; MARPAT 149:493695
                                           JP 2007-90650 A 20070330
```

FILE 'REGISTRY' ENTERED AT 10:26:08 ON 22 JAN 2009

STRUCTURE UPLOADED

GΙ

The title compds. I [A1 = (CH2)n; R1 = (un)substituted alkyl,AΒ (un) substituted cycloalkyl, (un) substituted Ph, etc.; R2 = (un) substituted amino, H, alkyl, etc.; X1 = H, halo; A = N, CX2; X2 = H, cyano, halo, etc.; X2 and R1 and a part of the main nucleus may be united to form an (un) substituted ring; W = CHR5, O, NR6; R5 = H, halo, (un) substituted alkyl, etc.; R6 = H, alkyl, cycloalkyl; Y = H, alkyl, amino (connected to an optional C atom on the saturated hetero ring), etc.; n = 0 - 2; R3, R4 = H, halo, (amino-substituted) cycloalkyl, etc.; further details related to R3 and R4 are given] are prepared by reaction of a haloquinolonecarboxylic acid derivative with a cyclic amine salt and a boron derivative in a solvent in the presence of a base. I are antibacterials (no data). Thus, 1-cyclopropyl-1, 4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4oxo-3-quinolinecarboxylic acid was prepared by reaction of 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3quinolinecarboxylic acid with 2-methylpiperazine dihydrochloride in acetonitrile containing triethylamine and BF3-THF complex. ΙT 817194-48-2P

Ι

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of quinolonecarboxylic acid by reaction of haloquinolonecarboxylic acid with cyclic amine salt and boron compound in solvent in presence of base.)

RN 817194-48-2 CA

CN 3-Quinolinecarboxylic acid, 7-[(3R)-3-[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]-1-pyrrolidinyl]-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

10/560,823process 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT L18 ANSWER 2 OF 10 CA COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 146:387110 CA TITLE: Method for production of quinolone-containing lyophilized preparation INVENTOR(S): Nishimoto, Norihiro PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan SOURCE: PCT Int. Appl., 61pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: Japanese FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. ____ _____ _____ WO 2006-JP319307 WO 2007037330 A1 20070405 20060928 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 1930006 A1 20080611 EP 2006-810754 20060928 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,

US 20080300403 A1 20081204 US 2008-67826 20080324 PRIORITY APPLN. INFO.: JP 2005-282393 A 20050928 WO 2006-JP319307 W 20060928

OTHER SOURCE(S): MARPAT 146:387110

BA, HR, MK, RS

AB Disclosed is a lyophilized preparation which contains only a quinolone-type synthetic anti-bacterial compound and a pH adjusting agent and has an excellent re-solubilizing property. Also disclosed is a method for production of a lyophilized preparation comprising a quinolone-type synthetic anti-bacterial compound as an active ingredient. The method comprises the steps of cooling an aqueous solution containing a quinolone-type synthetic anti-bacterial compound and a pH adjusting agent to yield a frozen material, increasing the temperature temporarily, and re-cooling the material to lyophilize the material.

IT 431058-65-0P

RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

 $\mbox{(manufacture of lyophilized prepns. containing quinolone-type antibacterials)} \\$

RN 431058-65-0 CA

CN 3-Quinolinecarboxylic acid, 7-[(3R)-3-(1-aminocyclopropyl)-1-pyrrolidinyl]-

1-[(1R,2S)-2-fluorocyclopropy1]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX

Absolute stereochemistry.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:

143:172685 CA

TITLE:

Preparation of rifamycin iminomethylenyl quinolone derivatives effective against drug-resistant microbes INVENTOR(S): Ding, Charles Z.; Jin, Yafei; Longgood, Jamie C.; Ma,

Zhenkun; Li, Jing; Kim, In Ho; Minor, Keith P.;

Harran, Susan

PATENT ASSIGNEE(S): Cumbre Inc., USA

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.				
		WO 2005-US838				
W: AE, AG, AL,	AM, AT, AU, AZ,	BA, BB, BG, BR, BW, B	Y, BZ, CA, CH,			
CN, CO, CR,	CU, CZ, DE, DK,	DM, DZ, EC, EE, EG, E	S, FI, GB, GD,			
GE, GH, GM,	HR, HU, ID, IL,	IN, IS, JP, KE, KG, K	P, KR, KZ, LC,			
LK, LR, LS,	LT, LU, LV, MA,	MD, MG, MK, MN, MW, M	X, MZ, NA, NI,			
NO, NZ, OM,	PG, PH, PL, PT,	RO, RU, SC, SD, SE, S	G, SK, SL, SY,			
TJ, TM, TN,	TR, TT, TZ, UA,	UG, US, UZ, VC, VN, Y	U, ZA, ZM, ZW			
RW: BW, GH, GM,	KE, LS, MW, MZ,	NA, SD, SL, SZ, TZ, U	G, ZM, ZW, AM,			
AZ, BY, KG,	KZ, MD, RU, TJ,	TM, AT, BE, BG, CH, C	Y, CZ, DE, DK,			
EE, ES, FI,	FR, GB, GR, HU,	IE, IS, IT, LT, LU, M	C, NL, PL, PT,			
RO, SE, SI,	SK, TR, BF, BJ,	CF, CG, CI, CM, GA, G	N, GQ, GW, ML,			
MR, NE, SN,	TD, TG					
		US 2005-34279	20050112			
US 7238694						
EP 1723150	A1 20061122	EP 2005-705477	20050112			
R: AT, BE, BG,	CH, CY, CZ, DE,	DK, EE, ES, FI, FR, G	B, GR, HU, IE,			
IS, IT, LI,	LT, LU, MC, NL,	PL, PT, RO, SE, SI, S	K, TR			
PRIORITY APPLN. INFO.:		US 2004-536018P	P 20040113			

WO 2005-US838 W 20050112

OTHER SOURCE(S): CASREACT 143:172685; MARPAT 143:172685

GΙ

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AB Rifamycin 3-iminomethylenyl (-CH=N-) derivs. of formula I [A = quinolone group; X = alkylene, arylene, heterocyclylene, CO, C=N, O, etc.; R = H, acetyl, etc.] are prepared which have antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH = N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms. Thus, II was prepared from ciprofloxacin and 3-formylrifamycin SV. The prepared compds. have MIC values of 0.06-16 mcg/mL against Staphylococcus aureus ATCC 29213 RpoBH418Y.
- IT 861391-37-9P
 - RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (preparation of rifamycin iminomethylene quinolone derivs. as antimicrobial agents)
- RN 861391-37-9 CA
- CN Rifamycin, 3-[(E)-[[4-[[1-[1-(3-carboxy-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-7-quinolinyl)-3-pyrrolidinyl]cyclopropyl]amino]-1-piperidinyl]imino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A

PAGE 2-A | O OH

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 143:26640 CA

TITLE: Preparation of quinolone antibacterial agents

INVENTOR(S): Ellsworth, Edmund Lee; Taylor, Clarke Bentley; Murphy,

Sean Timothy; Rauckhorst, Mark Ryan; Starr, Jeremy Tyson; Hutchings, Kim Marie; Limberakis, Chris; Hoyer,

Denton Wade

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DA	ATE APPL	ICATION NO.	DATE
WO 2005049602	A1 20	0050602 WO 2	004-IB3666	20041105
W: AE, AG, AL,	AM, AT, A	AU, AZ, BA, BB,	BG, BR, BW, BY,	BZ, CA, CH,

```
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     NL 1027545
                          C2
                                20060117
                                            NL 2004-1027545
                                                                    20041118
PRIORITY APPLN. INFO.:
                                            US 2003-523071P
                                                                 Ρ
                                                                    20031118
                                            US 2004-605496P
                                                                 Ρ
                                                                    20040831
                         MARPAT 143:26640
OTHER SOURCE(S):
GΙ
```

$$\begin{bmatrix} R^4 & 0 & 0 \\ R^4 & & & \\ & & & \\ R^5 & R^1 & & I \end{bmatrix}$$

AB Compds. of formula I, e.g., 7-[3-(2-Cyanoethylamino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, can be used in a variety of applications including use as antibacterial agents. The compds., method of treatment using the compds., and formulations containing the compds. are claimed. Methods of preparation of the

compds. are exemplified. The compds. of the invention were tested against a variety of gram-neg. and gram-pos. organisms.

IT 852857-63-7P

RL: PAC (Pharmacological activity); RCT (Reactant); PREP (Preparation); THU (Therapeutic use); PREP (Preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of quinolone antibacterial agents)

RN 852857-63-7 CA

CN 3-Quinolinecarboxylic acid, 7-[(3S)-3-[1-[(2-cyanoethyl)amino]cyclopropyl]-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 142:93693 CA

TITLE: Process for preparation of quinolinone derivatives

INVENTOR(S): Muto, Makoto; Kitagawa, Yutaka

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.			KIND DATE					APPL	ICAT							
					A1 2004			 1229									
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NΙ,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MΖ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,
		SN,	TD,	ΤG													
EP	1634	879			A1		2006	0315		EP 2	004-	7461	09		2	0040	618
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	FΙ,	RO,	CY,	TR,	BG,	CZ,	EE,	HU,	PL,	SK				
US	2006	0122	396		A1		2006	0608		US 2	005-	5608	23		2	0051	215
PRIORIT	Y APP	LN.	INFO	.:						JP 2	003-	1752	12		A 2	0030	619
										WO 2	004-	JP86	07	1	W 2	0040	618
OTHER S	OURCE	(S):			MAR:	PAT	142:	9369.	3								

GΙ

AB This invention pertains to a method for position-selectively introducing an amino group into a difluorobenzoic acid compound; a novel process for producing quinolinone derivs. I [wherein A = a protecting group; R1 = alkyl]. For example, the compound I [where A = tert-BuO2C; R1 = Me] was prepared in a multi-step synthesis starting from 2,4-difluoro-3-methoxybenzoic acid and (3R)-3-[1-(tert-butoxycarbonylamino)cyclopropyl]pyrrolidine. This invention provides a convenient method for regioselective amination of difluorobenzoic acid compound

IT 817194-48-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of quinolinone derivs. via regioselective amination)

RN 817194-48-2 CA

CN 3-Quinolinecarboxylic acid, 7-[(3R)-3-[1-[[(1,1-dimethylethoxy)carbonyl]amino]cyclopropyl]-1-pyrrolidinyl]-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 10 CA COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 136:401768 CA

TITLE: Preparation of dehalogenoquinolinecarboxylic acid

derivatives, naphthyridine derivatives, and benzoxazine derivatives as antibacterial agents

INVENTOR(S): Denzoxazine derivatives as antibacterial agents Takahashi, Hisashi; Miyauchi, Rie; Itoh, Masao;

Takemura, Makoto; Hayakawa, Isao

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND DATE		APPLICATION NO.							DATE			
	2002				A1		2002										20011	119
	W:						AU,									_		
	•						DK,											
							IN,											
							MD,											
							SE,											
							ZA,				,	,	,	,	,	,	,	,
	RW:						MZ,			SZ	z, I	ΓZ,	UG.	ZM.	ZW.	AT,	BE,	CH.
							FR,											
							CM,											
CA	2429		,		A 1		2002	0523	,	CA	200	01-2	2429	440	,	2	20011	119
	2002		50		A		2002 2002	0527		ĀU	200)2-2	2405	0		2	20011	119
EP	1336	611			A1		2003											
EP	1336	611			В1		2007											
	R:		BE,	CH,	DE,	DK,	ES,		GB,	GI	R, I	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,
							RO,							·	·		·	
BR	2001	0153:	26	•	Α		2004	0225		BR	200	1-1	1532	6		2	20011	119
JP	3711	108			B2		2005	1026		JΡ	200	02-5	5434	88		2	20011	119
CN	1269 2298 3723 2292 2003 2003	817			С		2006	0816		CNT	200	ገገ (2220	7.4			20011	119
RU	2298	006			C2		2007	0427		RU	200	03-1	1147	43		2	20011	119
AT	3723	38			Τ		2007	0915		ΑТ	-200	า1 – (9965.	4 N		- 7	20011	119
ES	2292	642			Т3		2008	0316		ES	200	11-9	9965	40		2	20011	119
IN	2003	CN00	734		Α		2005	0415		ΙN	200)3-0	CN73	4		2	20030	514
ИО	2003	0022	55		Α		2003	0721		ИО	200)3-2	2255			2	20030	519
NO	3261	57			В1		2008											
US	2004	0063	754		A1		2004	0401		US	200)3-4	4320	43		2	20030	519
ZA	2003	0038	71		Α		2004			7. A	-200)3-7	3871			- 7	20030	519
MX	2003	PA04	437		А		2004	0504		MX	200)3-E	PA44	37		2	20030	
KR	7771	49			В1		2007	1119		KR	200)3-	7068:	35		2	20030	520
HK	1056	729			A1		2008	0206		ΗK	200	03-1	1091	28		2	20031	215
JP	2004	2695	44		А		2004	0930		JΡ	200	04 - 1	1565	17			20040	
JP	2005	1942	74		A1 A A		2005	0721		JΡ	200	04 - 3	3794.	55		2	20041	228
JP	3760	172			В2		2006	0329										
US	2007	0123	560		A1		2007	0531		US	200	06-6	5449	01		2	20061	226
RIORIT	Y APP	LN.	INFO	.:									3522				20001	
													2488				20010	
													5434				20011	
										WO	200)1-J	JP10	086	,	W 2	20011	
										US	200)3-4	1320	43		A1 2	20030	519
THER SO	DURCE	(S):			MAR!	PAT	136:	40176	58									

GI

The title compds. I [R1 = alkyl, etc.; R2 = alkylthio, H; further detail on R1 and R2 is given; R3 = H, Ph, etc.; R4 = alkyl, etc.; A = N, etc.; R5, R6 = alkyl, etc.; A1 = (CH2)n; n = 1 or 2] are prepared I exhibit broad and potent activity against gram-neg. and gram-pos. bacteria and against resistant bacteria. The title compound II in vitro showed MIC of 0.025 μ g/mL against P. aeruginosa 32121. Formulations are given.

Ι

431058-65-0P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dehalogenoquinolinecarboxylic acid derivs., naphthyridine derivs., and benzoxazine derivs. as antibacterial agents) 431058-65-0 CA

RN 431058-65-0 CA
CN 3-Quinolinecarboxylic acid, 7-[(3R)-3-(1-aminocyclopropyl)-1-pyrrolidinyl]1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 133:237871 CA

Preparation of cis-substituted TITLE:

aminocycloalkylpyrrolidine derivatives of

1,4-dihydro-4-oxoquinoline-3-carboxylic acids as

antimicrobial drugs

INVENTOR(S): Takemura, Makoto; Kimura, Youichi; Takahashi, Hisashi;

Kimura, Kenichi; Miyauchi, Satoru; Ohki, Hitoshi;

Sugita, Kazuyuki; Miyauchi, Rie

Daiichi Pharmaceutical Co., Ltd., Japan PATENT ASSIGNEE(S): SOURCE:

U.S., 67 pp., Cont.-in-part of Appl. No.

PCT/JP96/03440. CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.		KIND DAT	E Ā	APPLICATION NO.	DATE		
US 6121285 WO 9719072				 US 1998-82155 WO 1996-JP3440			
W: AL	, LC, LK,	BB, BG, BF LR, LT, LV	, CA, CN, , MG, MK,	CU, CZ, EE, GE, MN, MX, NO, NZ, AZ, BY, KG, KZ,	HU, IL, IS, JP, PL, RO, SG, SI,		
IE		MC, NL, PI		CH, DE, DK, ES, BJ, CF, CG, CI,			
ZA 9804273 US 6184388		A 199 B1 200		ZA 1998-4273 US 1999-397515	19980520 19990917		
PRIORITY APPLN.	INFO.:			JP 1995-304129 JP 1996-192637	A 19951122 A 19960723		
				WO 1996-JP3440 JP 1997-131413 JP 1997-140643	A2 19961122 A 19970521 A 19970529		
				US 1998-82155	A1 19980521		

OTHER SOURCE(S): MARPAT 133:237871

GΙ

The title compds. (I) [wherein R1, R6, and R7 = independently H or alkyl; AB R2 = H or (un)substituted alkyl; R3 = H, OH, halo, carbamoyl, alkyl, alkoxy, or alkylthio; one of R4 and R5 = H and the other is CH2OH, Me, OMe, or F; or R4 and R5 together = hydroxyimino, a polymethylene chain of 3-6 C's which form a spirocyclic structure together with the pyrrolidine ring or an alkoxyimino group; n = 1-3; R8 = (halo)alkyl, alkenyl, alkoxy, alkylamino, (un) substituted cycloalkyl or (hetero) aryl, etc.; R9 = H or alkylthio; X1 = H or halo; R10 = H, NH2, OH, SH, halomethyl, alkyl, alkenyl, or alkoxy; A1 = N or (un)substituted C; Y1 = H, Ph, acetoxymethyl, pivaloyloxymethyl, ethoxycarbonyl, etc.] were prepared I have excellent antimicrobial activity and are highly safe. Thus, 1-benzyloxycarbonyl-4-(R)-(1-tert-butoxycarbonylaminocyclopropyl)-3-(S)fluoropyrrolidine was dissolved in EtOH and hydrogenated using Pd/C. A solution of the residue and DMSO was mixed with TEA and 5-amino-6,7-difluoro-1-[2-(S)-fluoro-1-(R)-cyclopropyl]-1,4-dihydro-8methoxy-4-oxoquinoline-3-carboxylic acid to give II (43%). II was tested on 13 microbial strains and showed potent inhibition with MIC values ranging from \leq 0.003 μ g/mL to 0.39 μ g/mL. In an acute toxicity test on male mice, none of the five mice died upon administration of 150 mg/kg doses of II. ΤТ

190954-09-7P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 6-(aminocycloalkylpyrrolidinyl)-1,4-dihydro-4-oxoquinolines as antimicrobial agents by addition of

6-fluoro-1, 4-dihydro-4-oxoquinolines to aminocycloalkylpyrrolidines)

RN 190954-09-7 CA

CN 3-Quinolinecarboxylic acid, 5-amino-7-[(3R,4S)-3-(1-aminocyclopropyl)-4fluoro-1-pyrrolidinyl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 130:13992 CA

TITLE: Preparation and formulation of cis-disubstituted

aminocycloalkylpyrrolidine moiety-containing quinoline

and benzoxazine derivatives as bactericides Takemura, Makoto; Takahashi, Hisashi; Sugita,

Kazuyuki; Ohki, Hitoshi; Miyauchi, Satoru; Miyauchi,

Rie

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

INVENTOR(S):

PA:	FENT	NO.			KIN	D	DATE			APPL	ICAT	ION I	NO.		D.	ATE	
WO	9852	939			A1		19981126 WO 19					 JP22	 19		1	9980.	520
	W:	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ES,	FΙ,	GB,	GE,	GH,	GM,	GW,	HU,	ID,	IL,	IS,	JP,	KE,	KG,
							LS,										
		NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	UA,
		UG,	US,	UZ,	VN,	YU,	ZW										
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	DK,	ES,
		FΙ,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,
		CM,	GΑ,	GN,	ML,	MR,	ΝE,	SN,	TD,	ΤG							
ZA	9804	273			A		1998	1125		ZA 1	998-	4273			1	9980	520
CA	2289	605			A1		1998	1126		CA 1	998-	2289	605		1	9980	520
ΑU	9874	493			A		1998	1211		AU 1	998-	7449.	3		1	9980	520
EP	1020	459			A1		2000	0719		EP 1	998-	9217.	38		1	9980	520
ΕP	1020	459			В1		2005	0406									
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	FΙ														
BR	9810	235			А		2001	0918		BR 1	998-	1023	5		1	9980.	520
ΙN	1998	MA01	076		А		2005	0304		IN 1	998-1	MA10	76		1	9980	520
ΑT	2926	32			T		2005	0415		AT 1	998-	9217.	38		1	9980	520
ИО	9905	653			Α		2000	0121		NO 1	999-	5653			1	9991	118
MX	9910	715			Α		2000	0831		MX 1	999-	1071	5		1	9991	119

US 20020077345 A1 20020620 US 2001-985256 20011102
PRIORITY APPLN. INFO.: JP 1997-131413 A 19970521
JP 1997-140643 A 19970529
WO 1998-JP2219 W 19980520
US 1999-424112 A1 19991119

OTHER SOURCE(S): MARPAT 130:13992

AB The title compds. I [R1 represents hydrogen or alkyl; R2 represents hydrogen or alkyl; R3 and R5 represent each hydrogen; R4 represents hydroxy, halogeno, carbamoyl, alkyl, alkoxy or alkylthio; R6 and R7 represent each hydrogen or alkyl; A = (CH2)n; n is an integer of from 1 to 3; R4 and the substituent on the pyrrolidine ring of general formula Q1 are arranged at the cis-configuration; and Q is a partial structure represented by Q2; R8 = alkyl, etc.; R9 = H, etc.; further details on R9 and R8 are given; R10 = amino, etc.; X1 = halo, H; A1 = N, etc.; A2, A3 = N, C; further details on A2 and A3 are given; Y = H, etc.] are prepared Three compds. of this invention in vitro showed MIC values of 0.10 to 0.39 μg/mL against P. aeruginosa 32104.

IT 190954-09-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

 $\hbox{(preparation of cis-disubstituted aminocycloalkylpyrrolidine } \\ \hbox{moiety-containing}$

quinoline and benzoxazine derivs. as bactericides)

RN 190954-09-7 CA

CN 3-Quinolinecarboxylic acid, 5-amino-7-[(3R,4S)-3-(1-aminocyclopropyl)-4-fluoro-1-pyrrolidinyl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 127:50550 CA ORIGINAL REFERENCE NO.: 127:9645a,9648a

TITLE: Preparation and formulation of substituted

aminocycloalkylpyrrolidinylquinolines as medical

bactericides

INVENTOR(S): Takemura, Makoto; Kimura, Youichi; Takahashi, Hisashi;

Kimura, Kenichi; Miyauchi, Satoru; Ohki, Hitoshi

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PAT	CENT	NO.			KIN	D	DATE			APPL	ICAT	ION :	NO.		D.	ATE	
WO	9719	072			A1	_	1997	0529		WO 1	 996-	 JP34	40		1	9961	122
	W:	AL,	ΑU,	BA,	BB,	ВG,	BR,	CA,	CN,	CU,	CZ,	EE,	GE,	HU,	IL,	IS,	JP,
		KR,	LC,	LK,	LR,	LT,	LV,	MG,	MK,	MN,	MX,	NO,	NZ,	PL,	RO,	SG,	SI,
		SK,	TR,	TT,	UA,	US,	UZ,	VN,	ΑM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM
	RW:	KΕ,	LS,	MW,	SD,	SZ,	UG,	ΑT,	BE,	CH,	DE,	DK,	ES,	FΙ,	FR,	GB,	GR,
		ΙE,	ΙT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	ML,
		MR,	ΝE,	SN,	TD,	ΤG											
	2238				A1		1997	0529		CA 1	996-	2238	765		1	9961	122
ΑU	9675	898			А		1997	0611		AU 1	996-	7589	8		1	9961	122
ΑU	7078	89			В2		1999	0722									
CN	1207	738			А		1999	0210		CN 1	996-	1997	13		1	9961	122
CN	1119	343			С		2003	0827									
ΕP	9113	28			A1		1999	0428		EP 1	996-	9385	33		1	9961	122
ΕP	9113	28			В1		2006	0208									
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	FI														
NZ	3222				А		2000	0526		NZ 1	996-	3222	02		1	9961	122
TW	4026				В		2000	0821		TW 1	996-	8511	4493		1	9961	122
	3173				${ m T}$		2006				996-					9961	
	9113	-			Τ		2006				996-					9961	
ES	2258	780			Т3		2006	0901		ES 1	996-	9385	33		1	9961	122

10/560,823process

20000130	JΡ	1997-519602		19961122
19980722	ИО	1998-2297		19980520
20000919	US	1998-82155		19980521
20010206	US	1999-397515		19990917
	JΡ	1995-304129	A	19951122
	JΡ	1996-192637	A	19960723
	WO	1996-JP3440	W	19961122
	JΡ	1997-131413	A	19970521
	JΡ	1997-140643	A	19970529
	US	1998-82155	A1	19980521
	20000919	19980722 NO 20000919 US 20010206 US JP JP WO JP JP	19980722 NO 1998-2297 20000919 US 1998-82155	19980722 NO 1998-2297 20000919 US 1998-82155 20010206 US 1999-397515 JP 1995-304129 A JP 1996-192637 A WO 1996-JP3440 W JP 1997-131413 A JP 1997-140643 A

OTHER SOURCE(S): MARPAT 127:50550

AB The title compds. I [R1 = H, alkyl; R2 = H, (un)substituted alkyl; R3 = H, halo, etc.; R4, R5 = H, OH, etc.; further details on R4, R5 are given; R6, R7 = H, alkyl; A = (CH2)n; n = 1 - 3; Q = quinoline moiety or analog (generic structures given)] are prepared The title compound II (preparation given)

in vitro showed MIC of 0.1 μ g/mL against Pseudomonas aeruginosa 32121.

IT 190954-09-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted aminocycloalkylpyrrolidinylquinolines as medical bactericides)

RN 190954-09-7 CA

CN 3-Quinolinecarboxylic acid, 5-amino-7-[(3R,4S)-3-(1-aminocyclopropyl)-4-fluoro-1-pyrrolidinyl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)

L18 ANSWER 10 OF 10 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 125:247632 CA ORIGINAL REFERENCE NO.: 125:46285a,46288a

Preparation and formulation of heterocyclic compounds TITLE:

as medical bactericides

INVENTOR(S):

Takemura, Makoto; Kimura, Youichi; Kawakami, Katsuhiro; Kimura, Kenichi; Ohki, Hitoshi; Matsuhashi,

Norikazu; Kawato, Haruko

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	TENT NO.			KIN	D DATE	APPLICATION NO.		DATE	
WO	9623782 W: CA,					WO 1996-JP208		19960201	
						GB, GR, IE, IT, LU,	MC.	NL. PT. SE	
CA	2212007			С	20040914	CA 1996-2212007			
JР	08277284			Ā	19961022	JP 1996-16260		19960201	
					20060215				
						EP 1996-901518		19960201	
EP	807630			В1	20030507				
	R: AT,	BE,	CH,	DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	NL,	SE, MC, PT,	ΙE
TW	487701			В	20020521	TW 1996-85101378		19960201	
EP	1304329			A2	20030423	EP 2003-883		19960201	
EP	1304329			АЗ	20040915				
					20081015				
						GB, GR, IT, LI, LU,			IE
ΑT	239720			T	20030515	AT 1996-901518 PT 1996-901518		19960201	
PΤ	807630			T	20030829	PT 1996-901518		19960201	
ES	2198474			Т3	20040201	ES 1996-901518		19960201	
						AT 2003-883			
						NO 1997-3530		19970731	
					20030407				
						FI 1997-3207			
US	5849757			Α	19981215	US 1997-875678		19970804	

PRIORITY APPLN.	INFO.:	JP	1995-15614	А	19950202
		JP	1995-19478	Α	19950207
		JP	1995-19481	Α	19950207
		EP	1996-901518	А3	19960201
		WO	1996-JP208	W	19960201

OTHER SOURCE(S): MARPAT 125:247632 GI

$$R^1$$
 O CO_2R F NH_2 O CO_2H R^2 A N X^2 I NH_2 I I

AB The title compds. I [X1 represents halo or hydrogen; X2 represents halo; R1 represents hydrogen, hydroxy, thiol, halomethyl, amino, alkyl or alkoxy; R2 represents a pyrrolidine moiety (generic structure given); A represents nitrogen, etc.; and R represents hydrogen, Ph, acetoxymethyl, pivaloyloxymethyl, ethoxycarbonyl, choline, dimethylaminoethyl, 5-indanyl, etc.] are prepared The title compound II (preparation given) in vitro showed MIC

values of \leq 0.003 $\mu g/mL$ and 0.05 $\mu g/mL$ against E. coli NIHJ and P. aeruginosa 32104, resp.

IT 181941-18-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as medical bactericides)

RN 181941-18-4 CA

CN 3-Quinolinecarboxylic acid, 7-[3-(1-aminocyclopropyl)-1-pyrrolidinyl]-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-, [1R-[1 α (R*),2 α]]- (9CI) (CA INDEX NAME)

```
=> d his
     (FILE 'HOME' ENTERED AT 10:19:32 ON 22 JAN 2009)
    FILE 'CASREACT' ENTERED AT 10:19:43 ON 22 JAN 2009
L1
               STRUCTURE UPLOADED
L2
             0 S L1 SAM
L3
             0 S L1 FULL
    FILE 'CASREACT, CHEMINFORMRX, DJSMONLINE, PS' ENTERED AT 10:20:21 ON 22
    JAN 2009
L4
             0 S L1
L5
              STRUCTURE UPLOADED
L6
             0 S L5
    FILE 'REGISTRY' ENTERED AT 10:24:33 ON 22 JAN 2009
L7
             STRUCTURE UPLOADED
L8
               STRUCTURE UPLOADED
             5 S L7 FULL
L9
            19 S L8 FULL
L10
    FILE 'CA' ENTERED AT 10:25:29 ON 22 JAN 2009
            1 S L9 FULL
L11
L12
            40 S L10 FULL
            1 S L11 AND L12
L13
    FILE 'REGISTRY' ENTERED AT 10:26:08 ON 22 JAN 2009
L14 STRUCTURE UPLOADED
L15
          148 S L14 FULL
    FILE 'CA' ENTERED AT 10:27:47 ON 22 JAN 2009
L16 88 S L15
L17
            1 S L16 AND L12
           10 S L10/PREP
L18
=>
---Logging off of STN---
=>
Executing the logoff script...
=> LOG Y
```

STN INTERNATIONAL LOGOFF AT 10:28:44 ON 22 JAN 2009